Etiological agents of bacteraemia and antibiotic susceptibility pattern in Kathmandu Model Hospital

Journal of the Nepal Medical Association

Volumn 46, Issue 167, 2007, Pages 112-118

  Amatya, Niroj Man ^a,b   Shrestha, B ^b   Lekhak, B ^a  

^a TU   (Nepal)

^b Kathmandu Model Hospital   (Nepal)

Author keywords

Bacteraemia; Ciprofloxacin resistant; Multidrug resistant; Salmonella

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CEFIXIME; CEFOTAXIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; NALIDIXIC ACID; OFLOXACIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIUM CULTURE; BACTERIUM EXAMINATION; BACTERIUM ISOLATION; BLOOD SAMPLING; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HUMAN; KIRBY BAUER DISC DIFFUSION; MENINGITIS; MICROBIAL GROWTH; MULTIDRUG RESISTANCE; NEPAL; NONHUMAN; PNEUMONIA; PROSPECTIVE STUDY; SALMONELLA PARATYPHI; SALMONELLA TYPHI; SENSITIVITY ANALYSIS; SEROTYPE; TYPHOID FEVER;

ANTI-INFECTIVE AGENTS; BACTEREMIA; CIPROFLOXACIN; HUMANS; MICROBIAL SENSITIVITY TESTS; PROSPECTIVE STUDIES; SALMONELLA PARATYPHI A; SALMONELLA TYPHI; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; TYPHOID FEVER;

EID: 42249102630     PISSN: 00282715     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. th ed. New York: CV. Mosby: 2002; p. 865-883.
2. Pokharel BM, Koirala J, Dahal RK, Mishra SK, Khadga PK Tuladhar NR. Multidrug-resistant and extended-spectrum beta-lactamase (ESBL)-producing Salmonella enterica (serotypes Typhi and Paratyphi A) from blood isolates in Nepal: surveillance of resistance and a search for newer alternatives. International Journal of Infectious Diseases 2006; 10(6): 434-438.
3. Sharma N, Koju R, Karmacharya B. Typhoid fever in Dhulikhel hospital, Nepal. Kathmandu University Medical Journal 2003; 2:188-192.
4. Murdoch DR, Woods CW, Zimmerman MD. The Etiology of Febrile Illness in Adults Presenting To Patan Hospital in Kathmandu, Nepal. American Journal of Tropical Medicine and Hygiene 2004; 70(6): 670-675.
5. Bhan MK, Bhal R, Bhatnagar S. Typhoid and paratyphoid fever. Lancet 2005; 366: 749-62.
6. Initiative for vaccine research (FVR), infectious diseases, WHO. [Online]. [Cited 2006 Dec 26]; Available from: URL: http://www.who.int/ vaccine_research/diseases/diarrhoeal/en/index7.html
7. Leibovici L, Shraga I, Drucker M, et al. The Benefit of Appropriate Empirical Antibiotic Treatment in Patients with Bloodstream Infection. J. Intern. Med 1998; 244: 379-386.
8. Aarestrup FM, Wiuff C, Molbak K, Threlfall EJ. Is it time to change fluoroquinolone breakpoints for Salmonella spp. Antimicrobial Agents and Chemotherapy. 2003; 47: 827-829.
9. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, document M7-A6. 2004 National Committee for Clinical Laboratory Standards, Wayne, Pa.
10. Ackers ML, Puhr ND, Tauxe RV, Mintz ED. Laboratory-Based Surveillance of Salmonella Serotype Typhi Infections in the United States: Antimicrobial Resistance on the Rise. JAMA 2000; 283: 2668-2673.
11. Threlfall EJ, Ward LR, Skinner JA, Smith HR, Lacey S. Ciprofloxacin-resistant Salmonella typhi and treatment failure. Lancet 1999; 353: 1590-1591.
12. Wain J, Kidgell C. The emergence of multidrug resistance to antimicrobial agents for the treatment of typhoid fever. Transactions of the Royal Society of Tropical Medicine and Hygiene 2004; 98(7): 423-430.
13. Mandal S, Mandal MD, Kumar NP. Reduced minimum inhibitory concentration of chloramphenicol for Salmonella enterica serovar typhi. Indian Journal of Medical Science 2004; 58: 16-23.
14. Nagesha CN, Rathis KC, Chandrasekharan MR. Multidrug resistant Salmonella typhi in Banglore, South India. Indian Journal of Medical Science 1994; 48(4): 85-8.
15. Lakshmi V, Ashok R, Susmita J, Shailaja VV. Changing trends in the antibiograms of Salmonella isolates at a tertiary care hospital in Hyderabad. Indian Journal of Medical Microbiology 2006; 24: 45-48.
16. Dutta P, Metre U, Dutta S, De A, Chatterjee MK, Bhattacharya SK. Ceftriaxone therapy in ciprofloxacin treatment failure typhoid fever in children. Indian J Med Res 2001; 113: 210-213.
17. Madhulika U, Harish BN, Parija SC. Current Pattern in Antimicrobial Susceptibility of Salmonella typhi isolates in Pondicherry. Indian J. Med. Res 2004; 120: 111-114.
18. Saha S, Talukdar SY, Islam M Saha S. A highly ceftriaxone resistant Salmonella typhi in Bangladesh. Pediatr. Infect.Dis. J 1999; 18: 387.
19. Shanahan PMA, Jesudason MV, Thomson CJ, Amyes SGB. Molecular Analysis of and Identification of Antibiotic Resistance Genes in Clinical Isolates of Salmonella typhi from India. Journal of Clinical Microbiology 1998; 36(6): 1595-1600.
20. Holt KE, Thomson NR, Wain J et al. Multidrug-Resistant Salmonella enterica Serovar Paratyphi A Harbors IncHI1 Plasmids Similar to Those Found in Serovar Typhi. Journal of Bacteriology 2007; 189(11): 4257-4264.
21. Tamang MD, Oh JY, Seol SY et al. Emergence of multidrug-resistant Salmonella enterica serovar Typhi associated with a class 1 integron carrying the dfrA7 gene cassette in Nepal. International Journal of Antimicrobial Agents 2007; 30(4): 330-335.
22. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid Fever. NEJM 2002; 347: 1770-1782.
23. Shirakawa T, Acharya B, Kinoshita S, Kumagai S, Gotoh A, Kawabata M. Decreased susceptibility to fluoroquinolones and gyrA gene mutation in the Salmonella enterica serovar Typhi and Paratyphi A isolated in Kathmandu, Nepal, in 2003. Diagn Microbiol Infect Dis 2006; 54(4): 299-303.
24. Turner AK, Nair S, Wain J. The acquisition of full fluoroquinolone resistance in Salmonella typhi by accumulation of point mutations in the topoisomerase targets. Journal of Antimicrobial Chemotherapy 2006; 58(4): 733-740.
25. Gaind R, Paglietti B, Murgia M et al. Molecular characterization of ciprofloxacin-resistant Salmonella enterica serovar Typhi and Paratyphi A causing enteric fever in India. Journal of Antimicrobial Chemotherapy 2006; 58(6): 1139-1144.
26. Parry CM, Ho VA, Phuong LT et al. Randomized Controlled Comparison of Ofloxacin, Azithromycin, and an Ofloxacin-Azithromycin Combination for Treatment of Multidrug-Resistant and Nalidixic Acid-Resistant Typhoid Fever. Antimicrobial Agents and Chemotherapy 2007; 51(3): 819-825.